Previous 10 | Next 10 |
2023-06-23 13:11:51 ET Gainers: Ault Alliance ( AULT ) +21% . Smith & Wesson Brands ( SWBI ) +19% . Oncolytics Biotech ( ONCY ) +18% . Lyra Therapeutics ( LYRA ) +19% . Argo Blockchain ( ARBK ) +16% . Golden Heaven Group ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 15, 2023, the company granted stock options to purchase an aggreg...
2023-05-04 12:25:24 ET Stoke Therapeutics press release ( NASDAQ: STOK ): Q1 GAAP EPS of -$0.53 beats by $0.15 . Revenue of $5.15M (+71.7% Y/Y) beats by $1.65M . For further details see: Stoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5....
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the BofA Securities Health Care Conference on Thursday, M...
2023-04-26 10:30:53 ET For further details see: Stoke Therapeutics a buy at Canaccord on platform for genetic diseases
2023-04-25 11:58:17 ET Stoke Therapeutics ( NASDAQ: STOK ) stock rose ~5% on Tuesday after the company said that U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) authorized an application seeking to start a phase 1/2 trial of STK-002 to treat autosomal do...
– Company advancing second TANGO ASO into the clinic – – STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve disorder – Stoke Therapeutics, Inc. (Nasdaq: STOK...
– Dosing anticipated to start in the coming weeks – – Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t...
2023-03-06 07:24:32 ET Stoke Therapeutics press release ( NASDAQ: STOK ): Q4 GAAP EPS of -$0.65 beats by $0.05 . Revenue of $3.27M beats by $0.41M . As of December 31, 2022, Stoke had $230.2 million in cash, cash equivalents, marketable securities, and restrict...
– Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 – – Company on track to provide additional safety and seizure frequency data from patients who r...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...